Eledon Pharmaceuticals
Open
$3.61
Prev. Close
$3.61
High
$3.64
Low
$3.61
Market Snapshot
$200.17M
-4.3
-1.31
33
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Eledon Pharmaceuticals CEO Ronen Twito prioritizes NCEL-101 as the key long-term value driver for the company's future growth and strategic direction.
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 31 full-time employees. The company went IPO on 2014-09-17. The firm is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
Recently from Cashu
Eledon Pharmaceuticals Expands Gene Therapy Pipeline for Autoimmune Diseases and Clinical Innovation
Eledon Pharmaceuticals Enhances Its Gene Therapy Pipeline Eledon Pharmaceuticals, a company specializing in gene therapies for the treatment of autoimmune diseases, announces a significant advancement…
Eledon Pharmaceuticals: Summary of Recent Developments and Stock Performance
To provide an accurate summary, I would need the specific text or article you would like me to summarize. Please provide the text so I can assist you effectively.
Eledon Pharmaceuticals: Key Developments and Future Outlook for Investors
Please provide the content you'd like summarized, and I'll be happy to assist you!
Eledon Pharmaceuticals: Summary Request for Content Not Provided.
I'm sorry, but it seems you haven't provided the text to summarize. Please share the relevant content about Eledon Pharmaceuticals, and I will assist you in creating the summary as requested.